解码原发性开角型青光眼:多组学方法识别可成药效应基因
本研究整合欧洲POAG GWAS与六类多组学xQTL,用多性状共定位识别效应变异,并用遗传风险评分和药物靶点优先级评估跨人群相关性与治疗潜力。共识别25个与至少一种xQTL共定位的POAG效应变异,其在非欧洲人群中效应量相关性更强、等位基因频率变异更小,基于效应变异的GRS表现与全基因组显著SNP的GRS相当,药物优先级分析提示锌、铜、舒尼替尼、普罗布考和阿司咪唑为潜在共同治疗剂。
要点
- 识别25个与至少一种xQTL共定位的POAG效应变异。
- 效应变异在非欧洲人群中效应量相关性强于非共定位变异。
- 基于效应变异的GRS在非欧洲人群中表现与全基因组显著SNP的GRS相当。
核心结论
- 研究为青光眼分子机制提供深入见解,效应变异可用于开发更稳健的GRS模型和广泛有效的POAG治疗策略。
研究设计与样本
- 整合欧洲POAG GWAS与六类多组学分子数量性状位点(xQTL),采用多性状共定位识别候选效应变异。
- 用遗传风险评分(GRS)分析评估跨人群相关性,并通过药物靶点优先级评估治疗潜力。
主要发现
- 识别25个与至少一种xQTL共定位的POAG效应变异。
- 非欧洲人群中效应变异与欧洲人的效应量相关性高于非共定位变异:Pearson r2非洲0.85 vs. 0.71,东亚0.81 vs. 0.69,拉丁美洲0.91 vs. 0.75。
- 效应变异跨人群等位基因频率变异更小,平均四分位距(IQR)0.15 vs. 0.20。
- 基于效应变异的GRS在非欧洲人群中表现与基于全基因组显著单核苷酸多态性(SNP)的GRS相当。
- 药物优先级分析识别锌、铜、舒尼替尼、普罗布考和阿司咪唑为POAG及其亚型的潜在共同治疗剂。
关键数值与推荐
- 效应变异与至少一种xQTL共定位。
- 非欧洲人群效应量相关性Pearson r2:非洲0.85 vs. 0.71,东亚0.81 vs. 0.69,拉丁美洲0.91 vs. 0.75。
- 等位基因频率平均IQR:0.15 vs. 0.20。
临床怎么用
- 效应变异可用于构建跨人群更稳健的POAG遗传风险评分模型。
- 锌、铜、舒尼替尼、普罗布考和阿司咪唑被列为POAG及其亚型的潜在共同治疗剂,供进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Genomewide association studies (GWAS) have identified numerous primary open angle glaucoma (POAG) risk loci, yet most reside in non-coding regions with unclear function. Mapping these loci to effector genes can elucidate disease mechanisms, identify functionally conserved variants, improve cross-ancestry risk prediction by reducing population-specific noise, and uncover shared therapeutic targets. METHODS: Here, we integrate European POAG GWAS with six types of multi-omics molecular Quantitative Trait Locis (xQTLs) using multi-trait colocalization to identify candidate effector variants and evaluate their cross-population relevance using genetic risk score (GRS) analysis, and their therapeutic potential through drug target prioritization. RESULTS: We identified 25 POAG effector variants colocalized with at least one xQTLs. In non-European populations, effector variants showed stronger effect size correlations with Europeans than non-colocalized variants (Pearson r2 = African 0.85 vs. 0.71; East Asian 0.81 vs. 0.69; and Latin American 0.91 vs. 0.75). Effector variants also had smaller allele frequency variations across populations (average interquartile range [IQR] = 0.15 vs. 0.20). The genetic risk score based on effector variants performed comparably to the genome-wide significant single-nucleotide polymorphism (SNP)-based GRS in non-European populations. Drug prioritization identified zinc, copper, sunitinib, probucol, and astemizole as potential common therapeutic agents for POAG and its subtypes. CONCLUSIONS: Our findings offer deeper insight into the molecular mechanisms underlying glaucoma and effector variants for developing more robust GRS models and broadly effective therapeutic strategies for POAG.
引用
- Guo J, Yao Y, Lin H, et al. Decoding Primary Open-Angle Glaucoma: A Multi-Omics Approach to Identify Druggable Effector Genes. Invest Ophthalmol Vis Sci. 2026. PMID: 42725910. doi:10.1167/iovs.67.11.19
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。